Biotech Values

[bladerunner1717]

Brean Murray re-affirms "buy" rating on CLDX with $14 price target


Brean Murray Reaffirms Buy Rating on Celldex Therapeutics (CLDX)
December 10th, 2012 - 0 comments - Filed Under - by Latisha Jones

Celldex Therapeutics Inc logoCelldex Therapeutics (NASDAQ: CLDX)‘s stock had its “buy” rating reaffirmed by research analysts at Brean Murray in a report released on Monday. They currently have a $14.00 target price on the stock.

Celldex Therapeutics opened at 5.52 on Monday. Celldex Therapeutics has a 52-week low of $2.53 and a 52-week high of $6.71. The company’s market cap is $342.1 million.

Celldex Therapeutics last posted its quarterly earnings results on Thursday, November 1st. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by $0.01. The company had revenue of $3.11 million for the quarter, compared to the consensus estimate of $2.07 million. Celldex Therapeutics’s revenue was up 34.6% compared to the same quarter last year. Analysts expect that Celldex Therapeutics will post $-1.00 EPS for the current fiscal year.

Several other analysts have also recently commented on the stock. Analysts at Jefferies Group reiterated a “buy” rating on shares of Celldex Therapeutics in a research note to investors on Monday. Finally, analysts at Oppenheimer raised their price target on shares of Celldex Therapeutics from $6.00 to $8.00 in a research note to investors on Tuesday, October 2nd. They now have an “outperform” rating on the stock.


Bladerunner